LON:AREC Arecor Therapeutics (AREC) Share Price, News & Analysis GBX 62.90 +0.40 (+0.64%) As of 08:34 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Arecor Therapeutics Stock (LON:AREC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arecor Therapeutics alerts:Sign Up Key Stats Today's Range 62.50▼ 6550-Day Range 60▼ 7052-Week Range 42▼ 100Volume25,728 shsAverage Volume20,009 shsMarket Capitalization£23.75 millionP/E Ratio31.45Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target. Read More Receive AREC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AREC Stock News HeadlinesArecor Therapeutics CEO on advancing ultra-rapid insulin trial and oral GLP-1 - ICYMIApril 17, 2026 | proactiveinvestors.com.auArecor targets broader AT278 partnership as phase II trial nearsApril 13, 2026 | uk.finance.yahoo.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.June 26 at 1:00 AM | Behind the Markets (Ad)Arecor targets phase II trial for AT278 in 2026 - ICYMIFebruary 14, 2026 | uk.finance.yahoo.comArecor targets phase II insuling trial for 2026 after successful 2025February 11, 2026 | finance.yahoo.comRainbow Rare Earths, Cloudbreak Discovery, Valereum, Arecor Therapeutics, Wellnex LifeFebruary 9, 2026 | finance.yahoo.comArecor prioritises deal for phase II insulin trial as key 2026 objectiveFebruary 9, 2026 | uk.finance.yahoo.comPanmure Liberum reiterates 'buy' on Arecor with 251p target after cash beatFebruary 9, 2026 | uk.finance.yahoo.comSee More Headlines AREC Stock Analysis - Frequently Asked Questions How have AREC shares performed this year? Arecor Therapeutics' stock was trading at GBX 84.45 at the beginning of the year. Since then, AREC stock has decreased by 25.5% and is now trading at GBX 62.90. How were Arecor Therapeutics' earnings last quarter? Arecor Therapeutics plc (LON:AREC) announced its quarterly earnings data on Monday, April, 13th. The company reported $2.00 earnings per share (EPS) for the quarter. The firm earned $1.71 million during the quarter. Arecor Therapeutics had a net margin of 38.74% and a trailing twelve-month return on equity of 14.26%. How do I buy shares of Arecor Therapeutics? Shares of AREC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Arecor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arecor Therapeutics investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Lowe's Companies (LOW) and SNDL (SNDL). Company Calendar Last Earnings4/13/2026Today6/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryCoal Current SymbolLON:AREC CIKN/A Webwww.americanresourcescorp.com Phone44 1223 426 060FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 2 Trailing P/E Ratio31.45 Forward P/E RatioN/A P/E GrowthN/ANet Income-£10.68 million Net Margins38.74% Pretax MarginN/A Return on Equity14.26% Return on Assets-37.31% Debt Debt-to-Equity Ratio1.52 Current Ratio4.35 Quick Ratio6.24 Sales & Book Value Annual Sales£1.71 million Price / Sales13.86 Cash FlowGBX 12.40 per share Price / Cash Flow5.07 Book ValueGBX 16.58 per share Price / Book3.79Miscellaneous Outstanding Shares37,757,000Free FloatN/AMarket Cap£23.75 million OptionableNot Optionable Beta-0.18 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:AREC) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersProblems at SpaceX: time to get out?Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold Will Hit $4,900JPMorgan now sees gold hitting $4,900, and central banks are buying at a record 710 tonnes per quarter. Trump'...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker includedTired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
